Revance Therapeutics (RVNC) Tops Q1 EPS by 12c

Revance Therapeutics (NASDAQ: RVNC) reported Q1 EPS of ($0.71), $0.12 better than the analyst estimate of ($0.83). Revenue for the quarter came in at $75 thousand versus the consensus estimate of $70 thousand.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• Jefferies upgrades Shopify to Buy on AI commerce tailwinds, sees 30% upside
• Gold Royalty acquires two Nevada royalties for $0.8 million
• Light & Wonder to report Q2 results Aug. 4, reaffirms FY26 outlook